GLP-1 RAs are one of the ever-increasing number of important drug classes used in the management of T2DM and their role in primary care continues to grow. But when and in whom can they be used? And what impact do they have on disease progression and long-term complications?
This face-to-face meeting aims to provide you with practical information on how to optimise the use of GLP-1 RAs, in particular Ozempic® (semaglutide).
You will have the opportunity to:
Don’t miss this unique opportunity to attend a highly practical gold-standard educational event!
For enquiries on your registration or more information about the program please contact us at:
Novo Nordisk Meeting Secretariat